相关实验视频

Updated: Jan 8, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

在Tirabrutinib治疗复发初级中枢神经系统淋巴瘤的伪进展后的持久缓解:一个案例研究

Sayoko Okawara¹, Satoru Ide², Hiroaki Morimoto¹

¹Department of Hematology, University of Occupational and Environmental Health, Kitakyushu City, Japan, uoeh-u.ac.jp.

Case reports in hematology

|December 24, 2025

概括

提拉布鲁丁尼 (TIR) 可以在初级中枢神经系统淋巴瘤 (PCNSL) 患者中引起伪进展 (PSP). 仔细监测至关重要,以区分PSP与真正的进展,并避免停止有效治疗.

科学领域:

神经瘤学神经瘤学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

初级中枢神经系统淋巴瘤 (PCNSL) 是一种罕见且具有攻击性的淋巴瘤.
关于布鲁顿的氨酸激酶抑制剂 (BTKI),如Tirabrutinib (TIR) 在PCNSL中的免疫调节作用的数据有限.
TIR是第二代BTKi用于复发性/耐火性PCNSL.

研究的目的:

报告PCNSL患者用TIR治疗的第一个伪进展病例 (PSP).
突出区分真实疾病进展与免疫媒介PSP的重要性.

主要方法:

一个79岁的女性患者的病例报告,患有复发性PCNSL.
用提拉布鲁替尼 (TIR) 单疗法进行治疗.
随着时间的推移进行临床和放射学监测.

主要成果:

最初的瘤回归,其次是明显的再生 (表明进展).
尽管瘤扩大,但患者仍然无症状.
继续TIR导致复原和持续2年的缓解,没有进一步的治疗.
观察到的现象与免疫媒介伪进展 (PSP) 一致.

结论:

提拉布鲁替尼 (TIR) 可以诱导PCNSL.中免疫调节反应,包括伪进展 (PSP).
区分PSP与真正的疾病进展对于治疗管理至关重要.
通过仔细的临床和放射学评估,避免过早停止TIR治疗.

关键词:

BTKiKi 的意思是这是PCNSL的PCNSL.淋巴瘤淋巴瘤是什么伪进展的伪进展.耐火材料耐火材料耐火材料这就是Tirabrutinib.

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...